pharmacology of diabetes mellitus Flashcards

(31 cards)

1
Q

type one diabetes characteristics - common, population, onset, symptoms, insulin?

A

uncommon, 10% childhood, sudden onset, insulin needed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

characteristics of T2DM

A

adult onset, 90%, 40 years over, common, onset is gradual, may or may not have symptoms , insulin required by some people

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

best practice pharmacotherapy for T1DM

A

multiple daily injections, continous subcutaneous insulin infusions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

example of subcutaneous insulin infections

A

insulin pumos

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what is basal insulin

A

this is insulin that runs in the background

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is bolus insulin

A

this is insulin that is secreted in response to energy intake ans glucose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

is an insulin is short acting, when should you administer it

A

inject before eating

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

if an insulin is fast acting, when should you inject

A

after you have eaten

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is the pathophysiology of T2DM

A

when there is decreased insulin by the pancreas and increased glucagon secretion in islet cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

pharmacotherapy for T2DM

A

oral or injectable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

examples of oral pharmacotherapy management

A

medication by mouth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what injectable and oral medications would we want ideally for pharmacotherpay for T2DM

A

drugs that can help decreased blood sugar and chances of heart issues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what risk factors should be considered with T2DM

A

risk of heart issues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is biguanide, what does it do

A

enhances insulin sensitivity in live and peripheral tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what does biguanide activate

A

AMP - activated protien kinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

glucagon like peptide

A

injectable once a week, works to activate the incretin pathway

17
Q

sodium glucose co-transporter 2 inhibitor

A

works on the kidneys to get rid of extra glucose

18
Q

dipeptidyl peptidase-4 inhibitor

A

works to amplify the incretin pathway activation by inhibition of enzymatic breakdown of GLP-1 and GIP

19
Q

works to amplify the incretin pathway activation by inhibition of enzymatic breakdown of GLP-1 and GIP

A

dipeptidyl peptidase-4 inhibitor

20
Q

what is the incretin pathway

A

after eating, gut hormones are secreted into blood and enteroendocrine cells

21
Q

what is the role of the incretin pathway

A

to manage/regulate the amount of insulin secreted

22
Q

how does insulin work

A

activates insulin receptors to regulate metabolism of carbohydrates, fats and protien

23
Q

what do thiazolidinediones do?

A

they work to make the body more sensitive to insulin

24
Q

alpha glucosidase inhibitor

A

inhibits the pancreatic alpha-amylase and intesinal alpha glucosidase or delay the absorption of carbohydrates from the small intestine, lowering the effect on glucose levels

25
what are the most lethal treatment for t2dm
insulin secretagogues
26
how do insulin secretagogues work?
they activate sulfonylurea receptor on beta cell to stimute endogenous insulin secretion
27
how do anti-obesity agents work?
inhibit lipase
28
what are some considerations for agent characteristics concerning the pharmacotherapy of T2DM
blood glucose lowering the efficacy and durability, risk of inducing hypoglycemia, effect on weight, side effects, cost, cardioprotection
29
blood glucose lowering the efficacy and durability, risk of inducing hypoglycemia, effect on weight, side effects, cost, cardioprotection are what?
agent characteristics
30
what are some patient characteristics that should be considered when considering pharmacotherapy??
degree of hyperglycemia, risk of hypoglycemia, weight, comorbidities, preferences, access to treatment
31
what are some comorbidities
renal and hepatic issues, insulin secretagogues can increase this risk